For the year ending 2025-12-31, ZVSA had -$1,429,146 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Non-cash rent expense | 0 |
| Operating lease liability | 0 |
| Depreciation of fixed assets | 0 |
| Net loss | -24,952,378 |
| Impairment of in-process research and development | 18,647,903 |
| Stock-based compensation | 222,831 |
| Issuance of common stock pursuant to vendor agreements | 240,000 |
| Write-off of deferred offering costs | 57,238 |
| Deferred tax (benefit) provision | -851,659 |
| Prepaid expenses and other current assets | 46,766 |
| Accounts payable | 689,268 |
| Vendor deposits | 161,927 |
| Accrued expenses and other current liabilities | 717,255 |
| Net cash used in operating activities | -5,114,381 |
| Exercise of warrants | 0 |
| Payment of offering costs | 0 |
| At the market issuance of stock proceeds | 0 |
| Private placement of warrants | 1,999,791 |
| Warrant inducement offer - exercise proceeds | 2,051,852 |
| Exercise of pre-funded warrants | 210 |
| Registration and issuance costs associated with warrant issuance | 366,618 |
| Net cash provided by financing activities | 3,685,235 |
| Net decrease in cash | -1,429,146 |
| Cash - beginning of period | 1,530,924 |
| Cash - end of period | 101,778 |
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)